{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:28:05Z","timestamp":1780316885245,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s00393-006-0068-x","type":"journal-article","created":{"date-parts":[[2006,6,27]],"date-time":"2006-06-27T06:43:28Z","timestamp":1151390608000},"page":"285-289","source":"Crossref","is-referenced-by-count":13,"title":["Evidenzbasierte Therapie des Raynaud-Syndroms","Evidence-based therapy of Raynaud\u2019s syndrome"],"prefix":"10.1007","volume":"65","author":[{"given":"M.","family":"Distler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kyburz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"68_CR1","doi-asserted-by":"crossref","unstructured":"Anderson ME, Moore TL, Hollis S et al. (2002) Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud\u2019s phenomenon and systemic sclerosis. Rheumatology (Oxford) 41: 324\u2013328","DOI":"10.1093\/rheumatology\/41.3.324"},{"key":"68_CR2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/000331978904000705","volume":"40","author":"Arosio","year":"1989","unstructured":"Arosio E, Montesi G, Zannoni M et al. (1989) Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud\u2019s phenomenon. Angiology 40: 633\u2013638","journal-title":"Angiology"},{"key":"68_CR3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00105-003-0578-2","volume":"54","author":"Bali","year":"2003","unstructured":"Bali G, Aberer E (2003) Iloprost therapy in systemic sclerosis. Hautarzt 54: 845\u2013851","journal-title":"Hautarzt"},{"key":"68_CR4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/ard.54.3.197","volume":"54","author":"Belch","year":"1995","unstructured":"Belch JJ, Capell HA, Cooke ED et al. (1995) Oral iloprost as a treatment for Raynaud\u2019s syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 54: 197\u2013200","journal-title":"Ann Rheum Dis"},{"key":"68_CR5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/rheumatology\/32.5.357","volume":"32","author":"Brennan","year":"1993","unstructured":"Brennan P, Silman A, Black C et al. (1993) Validity and reliability of three methods used in the diagnosis of Raynaud\u2019s phenomenon. The UK Scleroderma Study Group. Br J Rheumatol 32: 357\u2013361","journal-title":"Br J Rheumatol"},{"key":"68_CR6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archinte.166.2.231","volume":"166","author":"Caglayan","year":"2006","unstructured":"Caglayan E, Huntgeburth M, Karasch T et al. (2006) Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 166: 231\u2013233","journal-title":"Arch Intern Med"},{"key":"68_CR7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.1991.tb05565.x","volume":"31","author":"Challenor","year":"1991","unstructured":"Challenor VF, Waller DG, Hayward RA et al. (1991) Subjective and objective assessment of enalapril in primary Raynaud\u2019s phenomenon. Br J Clin Pharmacol 31: 477\u2013480","journal-title":"Br J Clin Pharmacol"},{"key":"68_CR8","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/01.CIR.72.3.466","volume":"72","author":"Coffman","year":"1985","unstructured":"Coffman JD, Rasmussen HM (1985) Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud\u2019s phenomenon. Circulation 72: 466\u2013470","journal-title":"Circulation"},{"key":"68_CR9","doi-asserted-by":"crossref","unstructured":"Coleiro B, Marshall SE, Denton CP et al. (2001) Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40: 1038\u20131043","DOI":"10.1093\/rheumatology\/40.9.1038"},{"key":"68_CR10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0090-6980(01)00131-9","volume":"65","author":"Della","year":"2001","unstructured":"Della Bella S, Molteni M, Mocellin C et al. (2001) Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat 65: 73\u201383","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"68_CR11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0950-821X(88)80070-7","volume":"2","author":"De Trafford","year":"1988","unstructured":"De Trafford JC, Lafferty K, Potter CE et al. (1988) An epidemiological survey of Raynaud\u2019s phenomenon. Eur J Vasc Surg 2: 167\u2013170","journal-title":"Eur J Vasc Surg"},{"key":"68_CR12","first-page":"72","volume":"13","author":"Diehm","year":"1984","unstructured":"Diehm C, Muller-Buhl U, Mechterscheimer U, Morl H (1984) Local treatment with isosorbide dinitrate ointment in Raynaud\u2019s phenomenon. Vasa 13: 72\u201374","journal-title":"Vasa"},{"key":"68_CR13","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","volume":"42","author":"Dziadzio","year":"1999","unstructured":"Dziadzio M, Denton CP, Smith R et al. (1999) Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42: 2646\u20132655","journal-title":"Arthritis Rheum"},{"key":"68_CR14","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","volume":"112","author":"Fries","year":"2005","unstructured":"Fries R, Shariat K, von Wilmowsky H, Bohm M (2005) Sildenafil in the treatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy. Circulation 112: 2980\u20132985","journal-title":"Circulation"},{"key":"68_CR15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/29.2.89","volume":"29","author":"Goodfield","year":"1990","unstructured":"Goodfield MJ, Hume A, Rowell NR (1990) The acute effects of cigarette smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud\u2019s phenomenon. Br J Rheumatol 29: 89\u201391","journal-title":"Br J Rheumatol"},{"key":"68_CR16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.rdc.2005.04.006","volume":"31","author":"Grader-Beck","year":"2005","unstructured":"Grader-Beck T, Wigley FM (2005) Raynaud\u2019s phenomenon in mixed connective tissue disease. Rheum Dis Clin North Am 31: 465\u2013481","journal-title":"Rheum Dis Clin North Am"},{"key":"68_CR17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00315217","volume":"40","author":"Kallenberg","year":"1991","unstructured":"Kallenberg CG, Wouda AA, Meems L, Wesseling H (1991) Once daily felodipine in patients with primary Raynaud\u2019s phenomenon. Eur J Clin Pharmacol 40: 313\u2013315","journal-title":"Eur J Clin Pharmacol"},{"key":"68_CR18","first-page":"328","volume":"7","author":"Ko","year":"2002","unstructured":"Ko GD, Berbrayer D (2002) Effect of ceramic-impregnated \u201ethermoflow\u201c gloves on patients with Raynaud\u2019s syndrome: randomized, placebo-controlled study. Altern Med Rev 7: 328\u2013335","journal-title":"Altern Med Rev"},{"key":"68_CR19","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","volume":"50","author":"Korn","year":"2004","unstructured":"Korn JH, Mayes M, Matucci Cerinic M et al. (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50: 3985\u20133993","journal-title":"Arthritis Rheum"},{"key":"68_CR20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/rheumatology\/32.6.524-a","volume":"32","author":"La Civita","year":"1993","unstructured":"La Civita L, Pitaro N, Rossi M et al. (1993) Amlodipine in the treatment of Raynaud\u2019s phenomenon. Br J Rheumatol 32: 524\u2013525","journal-title":"Br J Rheumatol"},{"key":"68_CR21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1191\/1358863x02vm455oa","volume":"7","author":"Muir","year":"2002","unstructured":"Muir AH, Robb R, McLaren M et al. (2002) The use of Ginkgo biloba in Raynaud\u2019s disease: a double-blind placebo-controlled trial. Vasc Med 7: 265\u2013267","journal-title":"Vasc Med"},{"key":"68_CR22","unstructured":"Pope J, Fenlon D, Thompson A et al. (2000) Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev CD000953"},{"key":"68_CR23","unstructured":"Pope J, Fenlon D, Thompson A et al. (2000) Prazosin for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev CD000956"},{"key":"68_CR24","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","volume":"298","author":"Rademaker","year":"1989","unstructured":"Rademaker M, Cooke ED, Almond NE et al. (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud\u2019s phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 298: 561\u2013564","journal-title":"BMJ"},{"key":"68_CR25","doi-asserted-by":"crossref","unstructured":"Ramos-Casals M, Brito-Zeron P, Nardi N et al. (2004) Successful treatment of severe Raynaud\u2019s phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology (Oxford) 43: 1454\u20131456","DOI":"10.1093\/rheumatology\/keh340"},{"key":"68_CR26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s003930050070","volume":"57","author":"Riemekasten","year":"1998","unstructured":"Riemekasten G, Jepsen H, Burmester GR, Hiepe F (1998) Iloprost administration over 21 days as an effective therapy in systemic scleroderma \u2013 case report and review of the literature. Z Rheumatol 57: 118\u2013124","journal-title":"Z Rheumatol"},{"key":"68_CR27","doi-asserted-by":"crossref","unstructured":"Ruch DS, Holden M, Smith BP et al. (2002) Periarterial sympathectomy in scleroderma patients: intermediate-term follow-up. J Hand Surg [Am] 27: 258\u2013264","DOI":"10.1053\/jhsu.2002.29483"},{"key":"68_CR28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2133.1987.tb07356.x","volume":"117","author":"Rustin","year":"1987","unstructured":"Rustin MH, Almond NE, Beacham JA et al. (1987) The effect of captopril on cutaneous blood flow in patients with primary Raynaud\u2019s phenomenon. Br J Dermatol 117: 751\u2013758","journal-title":"Br J Dermatol"},{"key":"68_CR29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/archderm.138.1.99","volume":"138","author":"Sapadin","year":"2002","unstructured":"Sapadin AN, Fleischmajer R (2002) Treatment of scleroderma. Arch Dermatol 138: 99\u2013105","journal-title":"Arch Dermatol"},{"key":"68_CR30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00558230","volume":"37","author":"Schmidt","year":"1989","unstructured":"Schmidt JF, Valentin N, Nielsen SL (1989) The clinical effect of felodipine and nifedipine in Raynaud\u2019s phenomenon. Eur J Clin Pharmacol 37: 191\u2013192","journal-title":"Eur J Clin Pharmacol"},{"key":"68_CR31","doi-asserted-by":"crossref","unstructured":"Thompson AE, Pope JE (2005) Calcium channel blockers for primary Raynaud\u2019s phenomenon: a meta-analysis. Rheumatology (Oxford) 44: 145\u201350","DOI":"10.1093\/rheumatology\/keh390"},{"key":"68_CR32","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","volume":"44","author":"Thompson","year":"2001","unstructured":"Thompson AE, Shea B, Welch V et al. (2001) Calcium-channel blockers for Raynaud\u2019s phenomenon in systemic sclerosis. Arthritis Rheum 44: 1841\u20131847","journal-title":"Arthritis Rheum"},{"key":"68_CR33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/ard.50.11.800","volume":"50","author":"Torley","year":"1991","unstructured":"Torley HI, Madhok R, Capell HA et al. (1991) A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud\u2019s phenomenon secondary to connective tissue diseases. Ann Rheum Dis 50: 800\u2013804","journal-title":"Ann Rheum Dis"},{"key":"68_CR34","first-page":"71","volume":"18","author":"Van der Meer","year":"1987","unstructured":"Van der Meer J, Wouda AA, Kallenberg CG, Wesseling H (1987) A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud\u2019s phenomenon. Vasa Suppl 18: 71\u201375","journal-title":"Vasa Suppl"},{"key":"68_CR35","first-page":"1917","volume":"23","author":"Vayssairat","year":"1996","unstructured":"Vayssairat M (1996) Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud\u2019s phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. J Rheumatol 23: 1917\u20131920","journal-title":"J Rheumatol"},{"key":"68_CR36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMcp013013","volume":"347","author":"Wigley","year":"2002","unstructured":"Wigley FM (2002) Clinical practice. Raynaud\u2019s Phenomenon. N Engl J Med 347: 1001\u20131008","journal-title":"N Engl J Med"},{"key":"68_CR37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","volume":"120","author":"Wigley","year":"1994","unstructured":"Wigley FM, Wise RA, Seibold JR et al. (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120: 199\u2013206","journal-title":"Ann Intern Med"},{"key":"68_CR38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","volume":"41","author":"Wigley","year":"1998","unstructured":"Wigley FM, Korn JH, Csuka ME et al. (1998) Oral iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 41: 670\u2013677","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-006-0068-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-006-0068-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-006-0068-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T12:29:37Z","timestamp":1559046577000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-006-0068-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["68"],"URL":"https:\/\/doi.org\/10.1007\/s00393-006-0068-x","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}